ResMed (RMD.AX) Earnings Analysis

ResMed (RMD.AX) has no confirmed upcoming earnings date. Last quarter (2026-04-30) it beat with EPS 0.4146 AUD vs 0.4056 AUD est (+2.2%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E 18.58.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does RMD.AX next report earnings?

No confirmed upcoming earnings date is currently scheduled for RMD.AX. This page updates as the calendar is published.

RMD.AX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-300.4146 AUD0.4056 AUD+2.2%Beat
2026-01-290.4211 AUD0.4117 AUD+2.3%Beat
2025-10-303.59 AUD0.381 AUD+842.3%Beat
2025-01-300.3893 AUD0.3893 AUD0%Beat
2024-10-250.22 AUD0.21 AUD+4.8%Beat
2024-08-020.21 AUD0.21 AUD0%Beat

Beat rate: 6/6 (100%) over reported quarters with consensus data.

RMD.AX valuation and analyst view

Trailing P/E18.58
Trailing EPS10.374 AUD
Price / book4.35
Dividend yield1.24%
Market cap40.25B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is ResMed (RMD.AX)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for RMD.AX. This page updates as the calendar is published.

Did RMD.AX beat earnings last quarter?

In its 2026-04-30 report, RMD.AX posted EPS of 0.4146 AUD versus a 0.4056 AUD estimate — a beat of 2.2%.

What is RMD.AX's earnings track record?

Over the last 6 reported quarters with consensus data, RMD.AX beat estimates 6 times (100%).

What is RMD.AX's current P/E ratio and EPS?

RMD.AX trades at a trailing P/E of 18.58 on trailing EPS of 10.374446993281992 AUD.

What do analysts rate RMD.AX?

RMD.AX has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.